Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region

Ormeci N., Gulsen M. T., Sezgin O., Aghayeva S., Demir M., Koksal I., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, sa.2, ss.148-155, 2020 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/tjg.2020.19440
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.148-155
  • Anahtar Kelimeler: Hepatitis C virus, direct-acting antiviral agents, treatment, HEPATITIS-C VIRUS, DACLATASVIR PLUS SOFOSBUVIR, GENOTYPE 3 INFECTION, OPEN-LABEL, RIBAVIRIN, LEDIPASVIR, REGIMENS, DISEASE, LEDIPASVIR/SOFOSBUVIR, VELPATASVIR
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background/Aims: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates. This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan.